CNX Nifty

MediPharm Labs Signs Wide-Ranging Strategic Manufacturing and IP Licensing Agreement with Biopharmaceutical Leader Avicanna Inc.

Retrieved on: 
Thursday, May 14, 2020
CNX Nifty

Avicanna is a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products.

Key Points: 
  • Avicanna is a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products.
  • Additionally, Avicanna will grant MediPharm Labs a license to use proprietary Avicanna formulations to develop additional MediPharm Labs and white label branded products for the domestic and international market.
  • In commenting on the agreement, Aras Azadian, CEO of Avicanna said: This best-in-class partnership combines years of our leading R&D pre-clinical development and intellectual property with MediPharm Labs unparalleled quality and pharmaceutical-level manufacturing capacity.
  • This is an important and far-reaching agreement that makes great use of MediPharm Labs advanced pharma capabilities, GMP-certified production and international distribution expertise, said Pat McCutcheon, CEO of MediPharm Labs.

NICE Actimize and Infosys Announce Strategic Partnership to Offer End-to-End Financial Crime Solutions

Retrieved on: 
Wednesday, May 13, 2020
Banking, Technology, Professional services, Security, Other Technology, Telecommunications, Software, VoIP, Networks, Other Professional Services, Internet, Mobile, Wireless, Hardware, Data management, Finance, Consumer electronics, Consulting, BSE SENSEX, CNX Nifty, Infosys, Economy of India, Companies, Service companies, Regulatory compliance

Leveraging their respective experiences across financial crime management, NICE Actimize and Infosys will provide their market-leading regulatory and compliance solutions and services to support multiple industry sectors.

Key Points: 
  • Leveraging their respective experiences across financial crime management, NICE Actimize and Infosys will provide their market-leading regulatory and compliance solutions and services to support multiple industry sectors.
  • Ajay Vij, Senior Vice President and Head of Financial Services Business EMEA for Infosys, said, We look forward to elevating our partnership with NICE Actimize, known for its market-leading financial crime solutions.
  • NICE Actimizes financial crime leadership combined with Infosys proven expertise in delivering business solutions will create significant efficiencies for financial services organizations.
  • NICE Actimize is the largest and broadest provider of financial crime, risk and compliance solutions for regional and global financial institutions, as well as government regulators.

Infosys Selected as the Digital Transformation Partner for GLOBALFOUNDRIES' Digital Leadership Program

Retrieved on: 
Wednesday, May 13, 2020
Companies, BSE SENSEX, CNX Nifty, Infosys, GlobalFoundries, Economy of India, Service companies, Digital transformation, GF

BENGALURU, India, May 13, 2020 /PRNewswire/ -- Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, has been selected by GLOBALFOUNDRIES (GF), the world's leading specialty foundry, as its partner for the company's Digital Transformation program.

Key Points: 
  • BENGALURU, India, May 13, 2020 /PRNewswire/ -- Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, has been selected by GLOBALFOUNDRIES (GF), the world's leading specialty foundry, as its partner for the company's Digital Transformation program.
  • Infosys will also enable GF's internal teams with next-gen digital skills to help co-deliver great user experiences across the enterprise.
  • Anand Swaminathan, EVP and Global Industry Leader - Communications, Media and Technology, Infosys,said, "Together with GlobalFoundries we are embarking on an industry leading digital transformation program.
  • We are excited to partner with them on this digital leadership program which we believe will set a new benchmark for the industry."

Infosys Selected as the Digital Transformation Partner for GLOBALFOUNDRIES' Digital Leadership Program

Retrieved on: 
Wednesday, May 13, 2020
Companies, BSE SENSEX, CNX Nifty, Infosys, GlobalFoundries, Economy of India, Service companies, Digital transformation, GF

BENGALURU, India, May 13, 2020 /PRNewswire/ -- Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, has been selected by GLOBALFOUNDRIES (GF), the world's leading specialty foundry, as its partner for the company's Digital Transformation program.

Key Points: 
  • BENGALURU, India, May 13, 2020 /PRNewswire/ -- Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, has been selected by GLOBALFOUNDRIES (GF), the world's leading specialty foundry, as its partner for the company's Digital Transformation program.
  • Infosys will also enable GF's internal teams with next-gen digital skills to help co-deliver great user experiences across the enterprise.
  • Anand Swaminathan, EVP and Global Industry Leader - Communications, Media and Technology, Infosys,said, "Together with GlobalFoundries we are embarking on an industry leading digital transformation program.
  • We are excited to partner with them on this digital leadership program which we believe will set a new benchmark for the industry."

Cipla Enters Into a Licensing Agreement With Gilead to Expand Access to COVID-19 Treatment

Retrieved on: 
Wednesday, May 13, 2020
Biotechnology, Life sciences, Specialty drugs, BSE SENSEX, CNX Nifty, Cipla, Gilead Sciences, Industries

This agreement is part of Cipla's efforts to enhance global access to life-saving treatments for patients affected by the pandemic.

Key Points: 
  • This agreement is part of Cipla's efforts to enhance global access to life-saving treatments for patients affected by the pandemic.
  • Cipla will receive the manufacturing know-how from Gilead Sciences, Inc. to manufacture the API and Finished product at a commercial scale.
  • We are pleased to partner with Gilead for this cause and take this treatment to patients across countries after the required regulatory approvals.
  • At Cipla, it is our continuous endeavour to ensure that no patient is denied access to life-saving treatments.

Cipla Enters Into a Licensing Agreement With Gilead to Expand Access to COVID-19 Treatment

Retrieved on: 
Wednesday, May 13, 2020
Biotechnology, Life sciences, Specialty drugs, BSE SENSEX, CNX Nifty, Cipla, Gilead Sciences, Industries

This agreement is part of Cipla's efforts to enhance global access to life-saving treatments for patients affected by the pandemic.

Key Points: 
  • This agreement is part of Cipla's efforts to enhance global access to life-saving treatments for patients affected by the pandemic.
  • Cipla will receive the manufacturing know-how from Gilead Sciences, Inc. to manufacture the API and Finished product at a commercial scale.
  • We are pleased to partner with Gilead for this cause and take this treatment to patients across countries after the required regulatory approvals.
  • At Cipla, it is our continuous endeavour to ensure that no patient is denied access to life-saving treatments.

Nexa Resources S.A. Announces 1Q20 Results and Provides Update in Response to Covid-19

Retrieved on: 
Tuesday, May 12, 2020
Natural Resources, Other Natural Resources, Mining, Minerals, BSE SENSEX, CNX Nifty, Maruti Suzuki, Suzuki, Companies, Economy of India

Nexa Resources S.A. (Nexa Resources or Nexa or the Company) (NYSE: NEXA) (TSX: NEXA) has published its 1Q20 Results.

Key Points: 
  • Nexa Resources S.A. (Nexa Resources or Nexa or the Company) (NYSE: NEXA) (TSX: NEXA) has published its 1Q20 Results.
  • Smelting sales are also expected to decrease and the updated guidance range is 540-580kton, down 10% from our previous 2020 guidance.
  • Also in response to this unprecedented scenario, we have suspended our greenfield project development and decreased exploration investments to US$26 million.
  • Nexa did not experience any material disruption to metal sales in 1Q20.

Cyient reports the Q4 FY 20 financial results

Retrieved on: 
Thursday, May 7, 2020
CNX Nifty, Cyient, Outsourcing, Economy of India, Service companies, Business, Hyderabad

HYDERABAD, India, May 7, 2020 /PRNewswire/ -- Cyient(Estd: 1991, NSE: CYIENT), a global engineering and technology solutions company, todayreporteditsconsolidatedfinancialresults for the fourth quarter (Q4) of FY 2020 ending March 31, 2020.

Key Points: 
  • HYDERABAD, India, May 7, 2020 /PRNewswire/ -- Cyient(Estd: 1991, NSE: CYIENT), a global engineering and technology solutions company, todayreporteditsconsolidatedfinancialresults for the fourth quarter (Q4) of FY 2020 ending March 31, 2020.
  • Defense market spends seems to be promising and is expected to grow in this FY which gives Cyient an opportunity for growth.
  • Witnessed participation by more than 500 volunteers
    Cyient (Estd: 1991, NSE: CYIENT) provides engineering, manufacturing, geospatial, digital, networks, and operations management solutions to global industry leaders.
  • Cyient leverages the power of digital technology and advanced analytics capabilities, along with domain knowledge and technical expertise, to solve complex business problems.

Cyient reports the Q4 FY 20 financial results

Retrieved on: 
Thursday, May 7, 2020
CNX Nifty, Cyient, Outsourcing, Economy of India, Service companies, Business, Hyderabad

HYDERABAD, India, May 7, 2020 /PRNewswire/ -- Cyient(Estd: 1991, NSE: CYIENT), a global engineering and technology solutions company, todayreporteditsconsolidatedfinancialresults for the fourth quarter (Q4) of FY 2020 ending March 31, 2020.

Key Points: 
  • HYDERABAD, India, May 7, 2020 /PRNewswire/ -- Cyient(Estd: 1991, NSE: CYIENT), a global engineering and technology solutions company, todayreporteditsconsolidatedfinancialresults for the fourth quarter (Q4) of FY 2020 ending March 31, 2020.
  • Defense market spends seems to be promising and is expected to grow in this FY which gives Cyient an opportunity for growth.
  • Witnessed participation by more than 500 volunteers
    Cyient (Estd: 1991, NSE: CYIENT) provides engineering, manufacturing, geospatial, digital, networks, and operations management solutions to global industry leaders.
  • Cyient leverages the power of digital technology and advanced analytics capabilities, along with domain knowledge and technical expertise, to solve complex business problems.

Dr. Reddy's to release Q4 and full year FY 20 results on May 20, 2020

Retrieved on: 
Thursday, May 7, 2020
General Health, Pharmaceutical, Health, Life sciences, CNX Nifty, Articles, Dr. Reddy's Laboratories, Biotechnology, Industries, Biosimilar, Lupin Limited

The operator will provide instructions on asking questions before and during the call.

Key Points: 
  • The operator will provide instructions on asking questions before and during the call.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.